Hims & Hers Health, Inc. (HIMS) — Fundamental Analysis

Snapshot & Big Picture

Hims & Hers Health is a telehealth platform connecting consumers to licensed medical providers and pharmacy services across categories like hair loss, sexual health, mental health, weight management, and skincare. The company has grown from a niche men's wellness brand into a broader direct-to-consumer health platform. Over the past several years, HIMS has executed one of the more dramatic revenue scaling stories in the telehealth space, moving from $82.6 million in revenue in fiscal 2019 to $2.35 billion in fiscal 2025 — all while making a genuine turn toward profitability. Below is a summary of annual performance across key metrics.

Latest Quarter Snapshot (Q1 2026, ended March 31, 2026)

The most recent data — more current than the annual figures above — comes from the 10-Q filed May 11, 2026, covering the quarter ended March 31, 2026. This quarter tells a more cautious story than the full-year 2025 results suggest.

Q1 2026 saw gross margin compress sharply to 65.2%, down from 73.8% for full-year 2025 and well below the 79–82% range seen in 2023–2024. Operating and net margins turned materially negative again. This represents a significant step back from the profitability milestones achieved in fiscal 2024 and 2025, and warrants close attention in subsequent quarters to determine whether this is a temporary investment cycle or a structural pressure on unit economics.

Profitability

The multi-year profitability trend through fiscal 2025 is one of steady improvement. HIMS carried deeply negative operating margins in its early years — losing 90 cents on every revenue dollar at the operating level in 2019 — and methodically narrowed those losses as revenue scaled. The company crossed into positive operating and EBITDA territory for the first time in fiscal 2024, posting a 4.2% operating margin and $79M in EBITDA, then expanded both modestly in fiscal 2025 to a 4.5% operating margin and $160M in EBITDA. Net margin also turned positive, reaching 8.5% in 2024 and 5.5% in 2025.

However, the Q1 2026 quarter breaks this trend sharply. Gross margin fell to 65.2% — the lowest recorded in the dataset — and operating margin returned to -12.9%. This suggests elevated costs, potentially tied to the company's pharmacy buildout, increased marketing spend, or cost-of-goods pressure in newer product lines such as compounded GLP-1 medications. Whether fiscal 2026 as a whole reclaims the profitability of 2024–2025 remains an open question.

Financial Health

Liquidity: The current ratio has declined from a very high 7.43 in 2020 to 1.90 in fiscal year-end 2025, and further to 1.69 in Q1 2026. While this downward trend reflects a maturing balance sheet deploying cash into operations and investment rather than holding it idle, the ratio remains above 1.0, indicating the company can still cover near-term obligations with current assets. Debt-to-equity was not available in any of the filings reflected in this dataset, so leverage cannot be assessed from this data alone.

Capital Expenditures: CapEx data was not available in the 10-K filings for fiscal years 2019, 2020, or 2021. Starting from fiscal 2022, the picture is as follows:

Capital intensity has risen dramatically. From a lean 1.4% of revenue in 2022, CapEx surged to 10.3% of revenue in fiscal 2025 — a $242.6 million outlay. This jump likely reflects investment in pharmacy infrastructure and fulfillment capacity, consistent with HIMS bringing more compounding and dispensing in-house. The Q1 2026 CapEx-to-revenue ratio of 6.0% is lower than the full-year 2025 rate, though it's a single quarter and the annualized run rate could still be significant. Rising capital intensity means the business requires increasingly heavy reinvestment to support its growth, which is worth monitoring alongside free cash flow generation.

Growth

HIMS has compounded revenue at exceptional rates across multiple time horizons. The table below summarizes the pre-calculated trailing revenue CAGRs:

A 3-year revenue CAGR of 64.5% and a 5-year CAGR of 73.6% place HIMS among the fastest-growing consumer health companies of the past half-decade. The 10-year CAGR is unavailable because the company does not have 10 years of SEC filing history. These growth rates reflect the powerful tailwinds of telehealth adoption and, more recently, demand for GLP-1 and compounded weight-loss treatments — though sustaining this pace as the revenue base approaches $2.5 billion and beyond will become increasingly difficult.

Plain English Summary

Hims & Hers spent its first several years doing what most high-growth consumer tech and health companies do: burning cash aggressively to acquire customers and build infrastructure while revenues scaled rapidly. That story largely played out as hoped — revenues grew from under $83 million in 2019 to $2.35 billion in 2025, and the company crossed into genuine profitability in 2024 for the first time, sustaining it in 2025. Gross margins in the high-70s to low-80s range throughout 2021–2024 suggested a strong underlying business model. The concern coming out of the most recent quarter (Q1 2026) is real, though: gross margins fell sharply to 65%, losses returned at the operating and net level, and capital expenditures remain elevated as the company invests heavily in its own pharmacy operations. Whether this is a temporary growing pain tied to infrastructure build-out — particularly around compounded medications like GLP-1 drugs — or the beginning of a structural margin reset is the central question for investors right now. The balance sheet remains solvent with a current ratio above 1.6, but the days of a very large cash cushion are behind the company. HIMS is no longer a speculative pre-revenue story; it is a scaling business that has tasted profitability and must now prove it can sustain and expand those margins even as it invests aggressively in its next phase of growth.

Source Filings

• 10-Q filed May 11, 2026 — Quarter ended March 31, 2026
• 10-K filed February 23, 2026 — Fiscal Year ended December 31, 2025